Fluidigm Corporation has announced that its Singapore-based manufacturing facility has ramped up to full process R&D and manufacturing operations, less than a year after opening its doors. The startup boosts the Company's entry into the billion dollar real-time qPCR market, enabling production of BioMark arrays to supply high-end users.
Gajus Worthington, CEO, Fluidigm, said, "We view our Singapore operation as critical to our long-term success. This group has proven its mettle with production of our first product, TOPAZ screening chips. Now, we are poised for high-volume, low-cost manufacturing to meet the demand in a much larger market."
Fluidigm
